2017
Contrast Agents for MR Imaging
Czeyda-Pommersheim F, Martin DR, Costello JR, Kalb B. Contrast Agents for MR Imaging. Magnetic Resonance Imaging Clinics Of North America 2017, 25: 705-711. PMID: 28964460, DOI: 10.1016/j.mric.2017.06.011.ChaptersConceptsAdverse eventsContrast mediumMR imagingCommon adverse eventsOral MR contrast agentGadolinium-based contrastContrast agentsOral contrast agentSpecific clinical questionsExcellent safety recordCT contrast mediaIron-based agentVariety of agentsLower incidenceClinical questionsSpecific contrast agentsClinical useMR contrast agentsSafety recordAgentsImagingIncidencePharmacology
2012
19IN Does Molecular Triage Help to Identify Highly Sensitive Disease?
Pusztai L. 19IN Does Molecular Triage Help to Identify Highly Sensitive Disease? Annals Of Oncology 2012, 23: ix29. DOI: 10.1016/s0923-7534(20)32633-8.Peer-Reviewed Original ResearchResponse markersPredictive valueEstrogen receptor expressionHigher tumor proliferationTreatment response markersClass of drugsNegative predictive valuePositive predictive valueDriver eventsAdjuvant therapyPredictive biomarkersPredictive markerTreatment modalitiesTriage patientsVariety of agentsBaseline prognosisClinical trialsReceptor expressionBreast cancerSensitive diseaseHuman epidermal growth factorClinical utilityEpidermal growth factorChemotherapy sensitivityTumor proliferation
2001
New cytotoxic agents and schedules for advanced breast cancer
Burstein H, Bunnell C, Winer E. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-358. DOI: 10.1053/sonc.2001.26146.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCisplatinClinical Trials as TopicDeoxycytidineDocetaxelDoxorubicinEnzyme InhibitorsFemaleFluorouracilGemcitabineHumansLiposomesPaclitaxelTaxoidsTopoisomerase I InhibitorsTrastuzumabVinblastineVinorelbineConceptsAdvanced breast cancerBreast cancerSide effectsUse of chemotherapyCombination of chemotherapyNovel biological agentsNew cytotoxic agentsTreatment of womenSuch biological therapiesCytotoxic chemotherapyBiological therapyVariety of agentsClinical activityAvailable agentsBetter survivalChemotherapyOral chemotherapeuticsCancerCytotoxic agentsWomenBiological agentsAgentsTherapyImportant studiesNew cytotoxic agents and schedules for advanced breast cancer
Burstein H, Bunnell C, Winer E. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-358. PMID: 11498829, DOI: 10.1016/s0093-7754(01)90129-0.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCisplatinClinical Trials as TopicDeoxycytidineDocetaxelDoxorubicinEnzyme InhibitorsFemaleFluorouracilGemcitabineHumansLiposomesPaclitaxelTaxoidsTopoisomerase I InhibitorsTrastuzumabVinblastineVinorelbineConceptsAdvanced breast cancerBreast cancerSide effectsUse of chemotherapyCombination of chemotherapyNovel biological agentsNew cytotoxic agentsTreatment of womenSuch biological therapiesCytotoxic chemotherapyBiological therapyVariety of agentsClinical activityAvailable agentsBetter survivalChemotherapyOral chemotherapeuticsCancerCytotoxic agentsWomenBiological agentsAgentsTherapyImportant studies
1995
Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents
Corbett T, Valeriote F, Lorusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lowichik N, Biernat L, Foster B, Wozniak A, Lisow L, Valdivieso M, Baker L, Leopold W, Sebolt J, Bissery M, Mattes K, Dzubow J, Rake J, Perni R, Wentland M, Coughlin S, Shaw J, Liversidge G, Liversidge E, Bruno J, Sarpotdar P, Moore R, Patterson G. Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents. Pharmaceutical Biology 1995, 33: 102-122. DOI: 10.3109/13880209509067092.Peer-Reviewed Original ResearchSCID miceNude miceTumor modelHuman tumorsHuman tumor xenograft modelsUnique histologic appearanceXenograft model systemAthymic nude miceHuman tumor modelsUnique biologic entityTumor xenograft modelClass of agentsNormal cellsDrug response profilesActivity testingTumor takeSolid tumor cellsVariety of agentsClinical trialsBiologic behaviorHistologic appearanceNew agentsXenograft modelSingle tumorSolid tumors
1994
Tourette's Disorder and Related Problems: A Review and Update
Coffey B, Miguel E, Savage C, Rauch S. Tourette's Disorder and Related Problems: A Review and Update. Harvard Review Of Psychiatry 1994, 2: 121-132. PMID: 9384893, DOI: 10.3109/10673229409017128.Peer-Reviewed Original ResearchConceptsTourette's disorderSerotonin reuptake inhibitorsNonmedication approachesNeuroleptic treatmentObsessive-compulsive disorderPsychiatric comorbidityVariety of agentsBasal gangliaModerate symptomsTricyclic antidepressantsCorticothalamic circuitVocal ticsLongitudinal followSevere symptomsStudy of childrenPsychiatric symptomatologyNeurological originMultifaceted conditionClinical settingObsessive-compulsive symptomsSymptomsDisordersNeuropsychological studiesFurther investigationTreatment
1991
Neuropeptide inhibition of voltage-gated calcium channels mediated by mobilization of intracellular calcium
Kramer R, Kaczmarek L, Levitan E. Neuropeptide inhibition of voltage-gated calcium channels mediated by mobilization of intracellular calcium. Neuron 1991, 6: 557-563. PMID: 1849723, DOI: 10.1016/0896-6273(91)90058-8.Peer-Reviewed Original ResearchConceptsThyrotropin-releasing hormoneVoltage-gated calcium channelsVoltage-gated Ca2Protein kinase CInactivation of Ca2Pituitary tumor cellsVariety of agentsHormone secretionNeurotransmitter inhibitionIntracellular calciumResult of Ca2Calcium channelsIntracellular Ca2Inhibits Ca2Kinase CEndocrine cellsRoutine useTumor cellsPatch-clamp electrodesPlasma membrane channelsDependent inactivationInhibitionHormoneSecretionCa2
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply